[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"candida-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:candida-infection":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,49,72,93],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100497742","oropharyngeal-candidiasis-opc-and-s-ecc-100497742",false,"NCT05761197","Oropharyngeal Candidiasis (OPC) and S-ECC","Association Between Early Candida Infection (Oral Thrush) and Severe Early Childhood Caries (S-ECC)","Oral-Thrush","Inclusion Criteria:\n\n* Male or female individuals at the age of 9-15-month-old\n* Must have at least one fully erupted tooth at baseline visit\n* Parent\u002Fguardian willing and able to provide informed consent\n* With or without a history of OPC (the study team will enroll 35 participants with and 35 participants without a history of OPC)\n\nExclusion Criteria:\n\n* Presence of a systemic medical condition (e.g. Down syndrome etc.)\n* Presence of an orofacial deformity\n* Presence of dental caries\n* Use of systemic antimicrobial therapy within 30 days of the baseline visit\n* Presence of any condition which, in the opinion of the investigator, makes participation in the project not in the individual's best interest.",true,"ALL","9 Months","15 Months",{"count":22,"type":23},70,"ESTIMATED","OBSERVATIONAL","The overall objective of this study is to investigate the association of early Candida infection (known as oral thrush or oropharyngeal candidiasis, OPC) in children during the first year of life with the onset and severity of severe early childhood caries (S-ECC).",[27,28,29],"Candida Infection","Oral Thrush","Early Childhood Caries",[31,32,33,34,35],"Oral candidiasis","Candida infection","Oral thrush","Early childhood caries","Oral Health","RECRUITING","2026-06-18",{"date":39,"type":40},"2026-06-22","ACTUAL",{"date":42,"type":40},"2024-09-01",{"date":44,"type":23},"2028-08-31",{"name":46,"class":47},"Temple University","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":18,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":48},"100616245","one-stage-exchange-in-candida-periprosthetic-infection-a-suitable-way-to-go-100616245","NCT07303101","One-stage Exchange in Candida Periprosthetic Infection a Suitable Way to go","CPCI","Inclusion Criteria:\n\n* Patient aged over 18 years at the time of prosthesis revision\n* Operated on at the Strasbourg University Hospitals (HUS) between January 1, 2013, and December 31, 2021\n* Hip or knee prosthesis revision\n* Possible or proven periprosthetic Candida spp. infection according to the EBJIS diagnostic criteria\n* Minimum of 3 deep samples (joint fluid, preoperative sample, and\u002For prosthesis sonication)\n\nExclusion Criteria:\n\n* Patient undergoing lavage, synovectomy, and implant preservation\n* Patient not receiving systemic antifungal treatment after prosthesis replacement\n* Patient with another proven Candida spp. infection or infective endocarditis\n* Patient for whom suppressive therapy was prescribed prior to surgery.","18 Years",{"count":58,"type":23},16,"Accounting for only 0.7% to 3% of joint prosthesis infections, yeast infections are considered particularly difficult to treat. They are primarily caused by Candida yeasts, representing over 90% of cases.\n\nSurgical treatment is the cornerstone of managing periprosthetic infections. In cases of chronic bacterial infections, complete implant replacement is necessary and can be performed either in one or two stages.\n\nHowever, for chronic Candida spp. infections, two-stage prosthesis replacement remains the preferred option. Only three retrospective, single-center studies have evaluated the success rate of one-stage prosthesis replacement in periprosthetic Candida spp. infections in selected patients. Although the sample sizes of these studies are small, the 2-year success rate of 63% to 81% differs little from that of two-stage implant replacement (47% to 100%). Furthermore, systemic antifungal treatment is poorly defined. Recommendations are based on studies with a low level of evidence. The hypothesis is that a single-stage prosthesis replacement combined with appropriate antifungal treatment for chronic periprosthetic Candida spp. infection has the same outcome as a two-stage prosthesis replacement.",[27],[32,62],"Prosthesis replacement","2025-12-11",{"date":65,"type":40},"2025-12-24",{"date":67,"type":40},"2025-05-28",{"date":69,"type":23},"2026-02",{"name":71,"class":47},"University Hospital, Strasbourg, France",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":4},"100611821","biofilm-formation-and-antifungal-resistance-in-candida-species-100611821","NCT07245563","Biofilm Formation and Antifungal Resistance in Candida Species","Biofilm Formation and Antifungal Resistance in Candida Species: A Comparative Study of Albicans and Non Albicans Strains in Hematology ICU.","Inclusion Criteria:\n\n* Eligible participants in the study were those with invasive infection and had one or more of this criteria :\n\noSuppressed general body immunity.\n\noSuppressed local body immunity as a result of trauma or invasive procedures.\n\noResistant to antibiotic therapy.\n\noNegative samples for bacterial examination and culture.\n\nCritical life threatening infect\n\nExclusion Criteria:\n\n* Patients who received antifungal therapy within 3 days prior to sample collection.\n\n  * Resistant to antibiotic therapy.",{"count":80,"type":23},300,"1. To determine the susceptibility pattern of our local isolated Candida strains which is essential for optimal management of fungal infection.\n2. Detection of biofilm formation by conventional and molecular methods\n3. Comparison between C. albicans and non-albicans in the prevalence of biofilm formation and biofilm -forming genes\n4. Find the association between antifungal resistance and biofilm formation in candida strains isolated from patients\n5. Determination of clinical factors associated with occurrence of infections.",[27],"NOT_YET_RECRUITING","2025-11-17",{"date":86,"type":40},"2025-11-24",{"date":88,"type":23},"2025-12-20",{"date":90,"type":23},"2026-10-12",{"name":92,"class":47},"Assiut University",{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":17,"sex":100,"minAge":101,"maxAge":4,"enrollmentInfo":102,"targetDuration":104,"studyType":24,"phases":4,"briefSummary":105,"conditions":106,"keywords":109,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":48},"100509073","safety-of-pregnant-subjects-exposed-to-ibrexafungerp-including-infant-outcomes-100509073","NCT05908682","Safety of Pregnant Subjects Exposed to Ibrexafungerp Including Infant Outcomes","A Single-arm Safety Study of Subjects Exposed to Ibrexafungerp Whilst Pregnant, Including Infant Outcomes Up to One Year","Inclusion Criteria:\n\n1. Exposure to ibrexafungerp during pregnancy or if conception is estimated to have occurred within 4 days of the last dose of ibrexafungerp\n2. Subject and\u002For parent\u002Flegal representative consents to participate and agrees to the conditions and requirements of the study including the interview schedule\u002Fcompletion of questionnaire and release of medical records\n\n   * Subject can be identified by the sponsor or HCP, in terms of confirmed pregnancy.\n\nA self-reported pregnancy will be considered as confirmed pregnancy if the Urine Pregnancy Test (UPT) result is positive.\n\n* A woman can self-enroll in the study or her healthcare provider (HCP), with her consent, can enroll her on her behalf.\n\nExclusion Criteria:\n\n1. Females who were not exposed to safety study medications during pregnancy\n2. Refusal to participate in the study\n3. An inability to provide an accurate medical history or give informed consent","FEMALE","0 Years",{"count":103,"type":23},100,"1 Year","This is an ongoing evaluation of subjects exposed to ibrexafungerp while pregnant. The study population will include pregnant women of any age.",[107,27,108],"Vulvovaginal Candidiasis","Vaginal Candidiasis",[110,111,112,113,114,115],"VVC","Thrush","BREXAFEMME","Candidiasis","Vaginal Yeast","Yeast Infection","2024-07-15",{"date":118,"type":40},"2024-07-17",{"date":120,"type":40},"2022-07-28",{"date":122,"type":23},"2029-10-31",{"name":124,"class":125},"Scynexis, Inc.","INDUSTRY"]